Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 2010788 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $4.40Day +0.00%Mkt cap $37M1Y −56.5%Off 52W high −76.1%Vol (1Y) 73.8%
Daily closing price, split-adjusted to the current basis; 1.4y shown of 364 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.2% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+0.00% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$9.7M |
| ROE−132.6% |
| ROIC−1449.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−59.6% |
| 1Y−56.5% |
| Since incept. (ann.)−61.6% |
Total return through 2026-07-29 · series begins 2025-02-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)73.8% |
| Ann. volatility (3Y)81.1% |
| Sharpe (1Y)−0.75 |
| Sharpe (3Y)−0.78 |
| Max drawdown (1Y)−73.3% |
| Max drawdown (3Y)−77.3% |
| Beta (3Y vs SPY)3.90 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 22,190 | $166,425 | 0.26% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 21,891 | $164,182 | 0.26% | −7.1% |
| VANGUARD FIDUCIARY TRUST CO | 9,426 | $70,695 | 0.11% | new |
| BlackRock, Inc. | 6,797 | $51,046 | 0.08% | +8.7% |
| Tower Research Capital LLC (TRC) | 1,317 | $9,891 | 0.02% | +65750.0% |
| MORGAN STANLEY | 1,250 | $9,388 | 0.01% | +0.0% |
| UBS Group AG | 24 | $180 | 0.00% | +700.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$0.28 | — | — | — |
| 2025-09-30 | 2025-11-13 | −$0.27 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$0.28 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$0.22 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
